Oligometastatic Disease Market: Epidemiology, Therapies, Companies, DelveInsight | ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company

Oligometastatic Disease emerging therapies, such as IMSA101, PNT2002 (177Lu-PNT2002), and others, are expected to boost the Oligometastatic Disease Market in the upcoming years.

DelveInsight has launched a new report on "Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Oligometastatic Disease, historical and forecasted epidemiology as well as the Oligometastatic Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Oligometastatic Disease market report @ https://www.delveinsight.com/report-store/oligometastatic-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Oligometastatic Disease Market Report:

According to DelveInsight's patient-based forecasting model, the market size for oligometastatic disease in the seven major markets (7MM) was approximately USD 1.9 billion in 2023, with strong growth expected through 2034 due to rising case numbers and the introduction of new therapies.
In March 2025, the FDA approved Pluvicto for earlier use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitors and are suitable candidates to delay chemotherapy. Novartis is also conducting Phase III trials to evaluate Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414) .
Oligometastatic disease represents an intermediate stage between localized and widespread cancer, typically involving one to five metastatic sites beyond the primary tumor.
In 2023, the U.S. accounted for about 40% of all oligometastatic cases within the 7MM. Common types include oligometastatic breast, prostate, colorectal, renal cell, and non-small cell lung cancers.
That year, the U.S. saw roughly 30,000 oligorecurrent cases, with non-small cell lung cancer accounting for the largest share.
Currently, there are no approved drugs for the treatment of oligometastatic disease. Few oligometastatic disease therapies are being investigated for the treatment of oligometastatic disease. Some of the key players involved in the development are ImmuneSensor Therapeutics (IMSA101), POINT Biopharma (PNT2002), and Novartis Pharmaceuticals (PLUVICTO).
In 2023, the United States reported the highest number of oligometastatic disease cases among the seven major markets (7MM), with approximately 117,800 cases, followed by Japan.
Oligometastasis commonly occurs in several cancer types, including breast cancer, non-small cell lung cancer (NSCLC), hormone-naive and castration-resistant prostate cancer, head and neck cancer, colorectal cancer, pancreatic cancer, and renal cell carcinoma. In the U.S., non-small cell lung cancer accounted for the highest number of oligometastatic cases that year.
In 2023, the United States accounted for the largest Oligometastatic disease market size among the 7MM, making ~50% of the total Oligometastatic disease market size of the 7MM.
Key Oligometastatic Disease companies such as ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company, and others are evaluating new drugs for Oligometastatic Disease to improve the treatment landscape.
Promising Oligometastatic Disease therapies include IMSA101, PNT2002 (177Lu-PNT2002), and others.

Oligometastatic Disease Overview

Oligometastatic disease refers to a form of cancer spread where cells from the primary tumor migrate to create a small number of metastatic tumors-usually in one or two additional locations. For example, colon cancer may spread to the liver, or breast cancer may result in a few tumors in the brain.

This condition is defined by a limited number of metastases, typically one to five distant sites beyond the original tumor. Unlike the traditional view that cancer spreads widely and progressively, the oligometastatic concept suggests that some patients may benefit from targeted local therapies aimed at controlling or even eliminating these limited metastases.

Oligometastatic Disease Market Outlook

Currently, there are no approved drug-based treatments for oligometastatic disease. Management primarily relies on localized therapies such as surgery and radiotherapy, which have demonstrated benefits in retrospective and small-scale studies. Phase II trials have indicated that combining definitive local treatments like stereotactic body radiotherapy (SBRT) or surgery with standard systemic therapies can improve progression-free survival (PFS) or overall survival (OS) in select patients.

In the absence of Phase III trial data, treatment decisions are largely guided by multidisciplinary tumor boards, which offer individualized recommendations based on the latest research and clinical best practices. These collaborative approaches have been shown to enhance outcomes, improve adherence to standard-of-care treatments, and provide more comprehensive care plans.

Several companies are actively developing therapies for oligometastatic disease, including ImmuneSensor Therapeutics, POINT Biopharma, Novartis, AstraZeneca, and Bristol-Myers Squibb. The current pipeline is limited, but a few promising therapies-such as IMSA101 (ImmuneSensor) and PNT2002 (POINT Biopharma)-are in Phase II trials and are expected to launch during the 2024-2034 forecast period.

Discover how the Oligometastatic Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/oligometastatic-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Oligometastatic Disease Emerging Drugs
IMSA101: ImmuneSensor Therapeutics
PNT2002 (177Lu-PNT2002): POINT Biopharma/Eli Lilly and Company

Scope of the Oligometastatic Disease Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Oligometastatic Disease Companies: ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company, and others
Oligometastatic Disease Therapeutic Assessment: Oligometastatic Disease current marketed and Oligometastatic Disease emerging therapies
Oligometastatic Disease Market Dynamics: Oligometastatic Disease market drivers and Oligometastatic Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Oligometastatic Disease Unmet Needs, KOL's views, Analyst's views, Oligometastatic Disease Market Access and Reimbursement

To know what's more in our Oligometastatic Disease report, visit https://www.delveinsight.com/report-store/oligometastatic-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Oligometastatic Disease Market Report:
Oligometastatic Disease market report covers a descriptive overview and comprehensive insight of the Oligometastatic Disease Epidemiology and Oligometastatic Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Oligometastatic Disease market report provides insights into the current and emerging therapies.
The Oligometastatic Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Oligometastatic Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Oligometastatic Disease market.

Got queries? Click here to know more about the Oligometastatic Disease market Landscape https://www.delveinsight.com/sample-request/oligometastatic-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Oligometastatic Disease Patient Share (%) Overview at a Glance
5. Oligometastatic Disease Market Overview at a Glance
6. Oligometastatic Disease Disease Background and Overview
7. Oligometastatic Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Oligometastatic Disease
9. Oligometastatic Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Oligometastatic Disease Emerging Therapies
12. Oligometastatic Disease Market Outlook
13. Country-Wise Oligometastatic Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Oligometastatic Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Oligometastatic Disease Market Outlook 2034 https://www.delveinsight.com/report-store/oligometastatic-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Oligometastatic Disease Pipeline Insights, DelveInsight

"Oligometastatic Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oligometastatic Disease market. A detailed picture of the Oligometastatic Disease pipeline landscape is provided, which includes the disease overview and Oligometastatic Disease treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.